|Sixty-seven dogs with HSA in different anatomic locations were evaluated retrospectively.
All dogs received the VAC protocol as an adjuvant to surgery (n = 50), neoadjuvant (n = 3), or as the sole treatment modality (n = 14).
There was no significant difference (P = 0.97) between the MST of dogs with stage III and stage I/II HSA.
For dogs presenting with splenic HSA alone, there was no significant difference between the MST of dogs with stage III and stage I/II disease (P = 0.12).
The overall response rate (complete response [CR] and partial response [PR]) was 86%).
No unacceptable toxicities were observed.
Dogs with stage III HSA treated with the VAC protocol have a similar prognosis to dogs with stage I/II HSA.
Dogs with HSA and evidence of metastases at the time of diagnosis should not be denied treatment.
Source: Francisco J. Alvarez, Kenji Hosoya, Ana Lara-Garcia, William Kisseberth, Guillermo Couto (2013): VAC Protocol for Treatment of Dogs with Stage III Hemangiosarcoma
In: Published online before print September 19, 2013, doi: 10.5326/JAAHA-MS-5954 Journal of the American Animal Hospital Association Nov/Dec 2013 jaaha.5954
Tell a friend
Send this article